Mesothelioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neurofibromatosis type 2 (NF2) gene, a tumor suppressor gene located on chromosome 22q12.2, is frequently abnormal in mesothelioma.
|
31231129 |
2020 |
Mesothelioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that express low levels of moesin-ezrin-radixin-like protein (merlin).
|
30785827 |
2019 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the current knowledge of molecular events triggered by <i>NF2</i>/merlin inactivation, which lead to the development of mesothelioma and other cancers, and discuss potential therapeutic targets in merlin-deficient mesotheliomas.
|
29587439 |
2018 |
Mesothelioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
NF2 mutations and/or Merlin inactivation are also seen in other cancers including some mesothelioma, breast cancer, colorectal carcinoma, melanoma and glioblastoma.
|
28692055 |
2017 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 29 patients with recurrent mesothelioma, the median progression-free survival was 12 weeks with 95% CI 9.1, 23.4 weeks (23.4 weeks merlin negative, n = 14; 11.4 weeks merlin positive, n = 9; 10.9 weeks merlin status unknown, n = 6).
|
27733373 |
2016 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Merlin loss is also found in a proportion of other cancers like mesothelioma, melanoma, breast cancer and glioblastoma.
|
25217104 |
2015 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Loss of merlin, a product of the neurofibromatosis 2 tumor suppressor gene, is being evaluated as a biomarker for FAK inhibitor sensitivity in mesothelioma.
|
24786638 |
2014 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, Axl positively regulates the oncogene Yes-associated protein, which is known to be under merlin regulation in schwannoma and is involved in increased proliferation of merlin-deficient meningioma and mesothelioma.
|
23318455 |
2014 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Our hypothesis was that in human mesothelioma without detectable NF2 mutations, regulators of NF2/merlin activity such as CPI-17 would be altered.
|
18835652 |
2009 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation.
|
18725387 |
2008 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation.
|
18725387 |
2008 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.
|
16652148 |
2006 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.
|
16319530 |
2005 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A mouse model recapitulating molecular features of human mesothelioma.
|
16166281 |
2005 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inactivating mutations of the neurofibromatosis type 2 (NF2) tumor suppressor gene merlin have been described in nearly 60% of primary malignant mesothelioma and in approximately 20% of the mesothelioma cell lines.
|
12673723 |
2003 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas.
|
12684666 |
2003 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region.
|
12168054 |
2003 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The NF2 gene is also implicated in the development of sporadic schwannomas and meningiomas, as well as tumor types seemingly unrelated to the NF2 disorder, such as malignant mesotheliomas.
|
14566860 |
2003 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in mesothelioma developed in mice presenting a heterozygous mutation of the Nf2 gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres.
|
12802287 |
2003 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Immunohistochemical analysis of the mesothelioma confirmed loss of expression of the NF2 protein, and comparative genomic hybridization revealed losses of chromosomes 14, 15, and 22, and gain of 7.
|
12136076 |
2002 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our data indicate that silencing of the NF2 gene is restricted to a subset of mesothelioma cell lines.
|
9679758 |
1998 |
Mesothelioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The rat NF2 gene was ubiquitously expressed as a 4.4-kb transcript in normal rat tissues as well as in rat mesothelioma cell lines.
|
9022813 |
1997 |
Mesothelioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the NF2 gene participates in the oncogenesis in a subset of mesotheliomas but not in lung cancers.
|
7882313 |
1995 |
Mesothelioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, malignant human tumors seemingly unrelated to the NF2 syndrome, such as neural crest-derived malignant melanomas, as well as malignant mesotheliomas (a pleural mesoderm-derived tumor), have also been found to be frequently mutated or deleted in the NF2 locus, suggesting a broader role for the NF2 gene in the initiation and progression of human neoplasms.
|
8586465 |
1995 |